Medifast, Inc.
MED · NYSE
Market closed$10.26$-0.240000 (-2.29%)After hours $10.28 · +0.19%
Key statistics
Previous close$10.50
Open$10.57
Day high$10.66
Day low$10.24
52-week high$15.37
52-week low$9.22
Market cap114.08M
Volume147.33K
Average volume219.89K
P/E ratio-11.27
Forward P/E—
EPS-0.91
Dividend yield0.00%
Market context
Why it moved
MED declined amid a broader market selloff, with futures pointing sharply lower and general weakness across sectors weighing on smaller healthcare and medical stocks.
What is happening
Recent company-specific developments and publisher coverage.
StreetInsider · July 18, 2026Medifast launches Trilivy, replacing its Optavia brandBusiness Wire · July 17, 2026Medifast Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health SystemInvesting.com · July 17, 2026Medifast rebrands weight loss program as TrilivyStock Titan · July 17, 2026Medifast (NYSE: MED) rebrands OPTAVIA as Trilivy metabolic health platformMarketBeat · July 15, 2026Medifast (NYSE:MED) Upgraded by Zacks Research to Strong-Buy RatingBusiness Wire · May 26, 2026Medifast Confirms Appointment of Nicholas Johnson as Chief Executive OfficerDirect Selling News · May 5, 2026Medifast Reports Q1 2026 Financial ResultsPR Newswire · April 14, 2026SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Medifast, Inc. (NYSE: MED) Mt Newswire · July 17, 2026Medifast Launches Trilivy Metabolic Health System Benzinga · July 17, 2026Medifast Launches Trilivy, Comprehensive Metabolic Health System; Co. Also Unveils Newly Formulated Meal Replacements, Including Trilivy Reset Fueling Line Enhanced With MetaVantage Technology Mt Newswire · May 26, 2026Medifast Names Nicholas Johnson as CEO Benzinga · May 4, 2026Medifast Affirms FY2026 GAAP EPS Guidance of $(2.75)-$(1.55) vs $(1.98) Est; Affirms FY2026 Sales Guidance of $270.000M-$300.000M vs $273.700M Est Benzinga · May 4, 2026Medifast Sees Q2 GAAP EPS $(1.00)-$(0.50) vs $(0.43) Est; Sees Sales $60.000M-$80.000M vs $74.700M Est Benzinga · May 4, 2026Medifast Q1 EPS $(0.19) Beats $(0.52) Estimate, Sales $76.044M Beat $69.200M Estimate Benzinga · March 20, 2026Medifast Agrees To Nominate Steamboat Capital Partners' Parsa Kiai, Jeff Rose As Independent Director Candidates Benzinga · February 20, 2026Medifast Announces Availability Of OPTAVIA's Comprehensive Metabolic Health System For Reimbursement On Select Insurance Plans Using Health Savings Accounts, Flexible Spending Accounts